Ask about this productRelated genes to: IL24 protein
- Gene:
- IL24 NIH gene
- Name:
- interleukin 24
- Previous symbol:
- ST16
- Synonyms:
- mda-7, IL10B, Mob-5, C49A, FISP, IL-24
- Chromosome:
- 1q32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-12-02
- Date modifiied:
- 2016-10-05
Related products to: IL24 protein
Related articles to: IL24 protein
- Radiofrequency microneedling (RFMN) is an emerging therapeutic approach that enhances skin rejuvenation by delivering targeted thermal injury to the dermal and subdermal layers while sparing the epidermis. However, the molecular mechanisms underlying its biological effects especially in comparison to medical microneedling remain poorly understood. In this study, we aimed to investigate, for the first time, the molecular and histological responses to RFMN using a standardized three-dimensional (3D) human skin model. As a secondary objective, we assessed the modulatory effects of RFMN aftercare treatment with a dexpanthenol-containing ointment. - Source: PubMed
Publication date: 2026/04/22
Huth SebastianMarquardt YvonneHuth LauraDjahed SinaBaron Jens Malte - How gut microbiota alterations may contribute to host inflammation and metabolomic profiles affecting atherosclerosis is not fully elucidated, especially in the context of HIV. - Source: PubMed
Publication date: 2026/05/04
Wang ZhengWang YiPeters Brandilyn APost Wendy SBrown Todd TPalella Frank JRinaldo Charles RWitt Mallory DGange Stephen JKuniholm Mark HSha Beverly EChichetto Natalie EClish Clary BGerszten Robert EHodis Howard NSharma AnjaliAnastos KathrynBurk Robert DKaplan Robert CQi QibinHanna David B - Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL-4 and IL-13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that exert their effects via the JAK, specifically IL-4, IL-13, and IL-31, comprehensive disease control requires additional approaches that modulate JAK-independent pathways. Factors such as TNF-α, IL-25, IL-33, microbial antigens, and physical stimuli activate mitogen-activated protein kinase and nuclear factor-κB signaling in a JAK-independent manner, sustaining the disease activity. Consequently, in some cases, a strategy incorporating topical treatment that inhibits JAK-independent pathways is indispensable alongside systemic treatment. One potential strategy of this kind involves the aryl hydrocarbon receptor (AhR), ligand-activated transcription factor. Under Th2-polarized conditions, the expression of indoleamine 2,3-dioxygenase 1 (IDO1) is downregulated, limiting the availability of tryptophan-derived metabolites. This scarcity of endogenous AhR ligands subsequently compromises physiological AhR signaling. Tapinarof, a therapeutic AhR-modulating agent (TAMA), activates AhR without generating excessive reactive oxygen species. This exerts multiple effects: enhancing antioxidant defenses via nuclear factor erythroid 2-related factor 2 (NRF2) activation, restoring barrier dysfunction, suppressing Th2 inflammation, and correcting abnormalities associated with pruritus-related molecules. Furthermore, clinical trials of tapinarof have demonstrated improvement of the disease activity and pruritus, with efficacy intensifying over long-term treatment. Although adverse events such as folliculitis, acne, contact dermatitis, and headache occur, they are generally manageable by adjusting the frequency of application based on their reversibility and time of onset. Moreover, considering potential antagonism by IL-24 induced by tapinarof, combining tapinarof with systemic agents, topical therapies, or phototherapy may serve to optimize the therapeutic effects. In conclusion, AhR functions as a molecular hub integrating AD pathology, and the TAMA tapinarof expands therapeutic strategies in the treatment of AD. - Source: PubMed
Publication date: 2026/04/29
Tsuji GakuFuyuno YokoKawamura KojiYumine AyakoTakemura MasakiMitamura YasutakaYamamura KazuhikoNakahara Takeshi - This study aims to elucidate the role of Enterococcusin the progression from inflammatory bowel disease to colorectal cancer (CRC), with a focus on identifying key metabolites and host genes regulated by Enterococcusand their influence on CRC development. - Source: PubMed
Publication date: 2026/03/30
Huang GangLiu JianiCheng ZhipengChen YixinChen KexinLiu WanLiu HancongXia XinhaoLu ManCui WenxiZhang QingqingYuan YiZhong FeiLiao Yiwen - Interleukin (IL)-24, a member of the IL-20 cytokine family, is secreted by multiple cell types, such as immune cells (T cells, B cells, NK cells, macrophages), and non-immune cells (epithelial cells and fibroblasts). IL-24 and its downstream signaling pathways mediate vital biological processes, including processes governing cell growth, fate determination, cell death, and inflammation, albeit with effects that are context-dependent across disease states. In this review, we present comprehensive summary and recent breakthroughs in IL-24 characterization and its emerging pathogenic functions in type 2 immune diseases, including chronic spontaneous urticaria (CSU), atopic dermatitis (AD), allergic contact dermatitis (ACD), bullous pemphigoid (BP), chronic nodular prurigo (CNPG), and allergic airway diseases, in an attempt to provide valuable insights for developing its potential as biomarkers or therapeutic targets. - Source: PubMed
Publication date: 2026/03/12
Song XiaotingLan DongLiu Fang